A total Series A financing round of ca $84m enables Quell to accelerate in engineered T regulatory (Treg) cell therapies, especially in its program in liver transplantation.
https://www.uktech.news/funding/london-biotech-quell-therapeutics-raises-a-total-of-604m-in-series-a
